[PPARgamma-activating properties of angiotensin receptor blockers].
Ando
Hitoshi
H
Division of Clinical Pharmacology, Department of Pharmacology, School of Medicine, Jichi Medical University.
Fujimura
Akio
A
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use; D001565:Benzoates / Q000494:pharmacology / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007333:Insulin Resistance; D000077405:Irbesartan; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000503:physiopathology; D047495:PPAR gamma / Q000819:agonists* / Q000502:physiology; D016032:Randomized Controlled Trials as Topic; D000077333:Telmisartan; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D001713:Biphenyl Compounds; D047495:PPAR gamma; D013777:Tetrazoles; D000077405:Irbesartan; D000077333:Telmisartan